The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Open accessAbstract
IMPORTANCE: Off-label use of prescription drugs has been identified as an important contributor to preventable adverse drug events (ADEs) in children. Despite concerns regarding adverse outcomes, to date, no systematic investigation of the effects of off-label drug use in adult populations has been performed. OBJECTIVE: To monitor and evaluate off-label use of prescription drugs and its effect on ADEs in an adult population. DESIGN, SETTING, AND PARTICIPANTS: A cohort of 46,021 patients who received 151,305 incident prescribed drugs was assembled from primary care clinics in Quebec, Canada, using the Medical Office of the XXIst Century electronic health record, which supports documentation of treatment indications and treatment outcomes. Prescriptions dispensed from January 1, 2005, through December 30, 2009, were followed up from the date of the prescription to the date the drug use was discontinued, the end of treatment, or the end of follow-up (December 30, 2010). Data were analyzed from January 5, 2012, to March 15, 2015. EXPOSURES: Off-label prescription drug use with and without strong scientific evidence. MAIN OUTCOMES AND MEASURES: Adverse drug events in off-label use with and without strong scientific evidence. Analysis used multivariate marginal Cox proportional hazards regression for clustered data with the drug as the unit of analysis. RESULTS: A total of 3484 ADEs were found in the 46,021 study patients, with an incidence rate of 13.2 per 10,000 person-months. The rate of ADEs for off-label use (19.7 per 10,000 person-months) was higher than that for on-label use (12.5 per 10,000 person-months) (adjusted hazard ratio [AHR], 1.44; 95% CI, 1.30-1.60). Off-label use lacking strong scientific evidence had a higher ADE rate (21.7 per 10,000 person-months) compared with on-label use (AHR, 1.54; 95% CI, 1.37-1.72). However, off-label use with strong scientific evidence had the same risk for ADEs as on-label use (AHR, 1.10; 95% CI, 0.88-1.38). The risks for ADEs were higher for drugs approved from 1981 to 1995 (14.4 per 10,000 person-months; AHR, 1.62; 95% CI, 1.45-1.80) and for those used by women (14.3 per 10,000 person-months; AHR, 1.17; 95% CI, 1.06-1.28), patients receiving 5 to 7 drugs (12.1 per 10,000 person-months; AHR, 3.23; 95% CI, 2.66-3.92), and patients receiving cardiovascular drugs (15.9 per 10,000 person-months; AHR, 3.30; 95% CI, 2.67-4.08) and anti-infectives (66.2 per 10,000 person-months; AHR, 6.33; 95% CI, 4.58-8.76). Patients with a 1-unit increase in the continuity of care index had a 19% increase in ADEs (AHR, 1.19; 95% CI, 1.12-1.26). CONCLUSIONS AND RELEVANCE: Off-label use of prescription drugs is associated with ADEs. Caution should be exercised in prescribing drugs for off-label uses that lack strong scientific evidence. Future electronic health records should be designed to enable postmarket surveillance of treatment indications and treatment outcomes to monitor the safety of on- and off-label uses of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Adverse Drug Events in Ambulatory Care
Gandhi, T. K., Weingart, S. N., Borus, J., Seger, A. C., Peterson, J., Burdick, E., Seger, D. L., Shu, K., Federico, F., Leape, L. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa020703 · Cited by 1,345
National Surveillance of Emergency Department Visits for Outpatient Adverse Drug Events
Budnitz, D. S., Pollock, D. A., Weidenbach, K. N., Mendelsohn, A. B., Schroeder, T. J., & Annest, J. L. (2006) · JAMA · doi:10.1001/jama.296.15.1858 · Cited by 893
Off-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711 · cited 2×
“Strong evidence exists when (1) the drug is effective or favors efficacy for the off-label treatment indication, (2) the drug is recommended for at least most patients with the off-label treatment indication, and (3) the Research Original Investigation Off-label Drug Use and Adverse Drug Events in Adults”
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Polypharmacy and Prescribing Quality in Older People
Steinman, M. A., Seth Landefeld, C., Rosenthal, G. E., Berthenthal, D., Sen, S., & Kaboli, P. J. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00889.x · Cited by 537
Tamblyn, R., Abrahamowicz, M., Dauphinee, D., Wenghofer, E., Jacques, A., Klass, D., Smee, S., Blackmore, D., Winslade, N., Girard, N., et al. (2007) · JAMA · doi:10.1001/jama.298.9.993 · Cited by 448
Self-citationAdmissions to hospital caused by adverse drug reactions: cross sectional incidence study
Pouyanne, P. (2000) · BMJ · doi:10.1136/bmj.320.7241.1036 · Cited by 444
Advances in Inflammation Research.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-6-885_1 · Cited by 387
Johnell, K., & Klarin, I. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00009 · Cited by 386
Bellera, C. A., MacGrogan, G., Debled, M., de Lara, C. T., Brouste, V., & Mathoulin-Pélissier, S. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-20 · Cited by 384
The Effect of Continuity of Care on Emergency Department Use
Gill, J. M. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.4.333 · Cited by 351
Regulating Off-Label Drug Use — Rethinking the Role of the FDA
Stafford, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0802107 · Cited by 350
Patient Risk Factors for Adverse Drug Events in Hospitalized Patients
Bates, D. W. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2553 · Cited by 330
The Ambiguous Relation between Aging and Adverse Drug Reactions
Gurwitz, J. H., & Avorn, J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-11-956 · Cited by 313
Tamblyn, R. M., Huang, A. R., Perreault, R. B., Jacques, A., Roy, D., Hanley, J. A., McLeod, P. J., & Laprise, R. (2003) · Europe PMC (PubMed Central) · Cited by 291
Self-citationComputerized Prescribing: Building the Electronic Infrastructure for Better Medication Usage
Schiff, G. D., & Rucker, T. D. (1998) · JAMA · doi:10.1001/jama.279.13.1024 · Cited by 247
Martin, R. M., Biswas, P. N., Freemantle, S. N., Pearce, G. L., & Mann, R. D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00817.x · Cited by 219
Zhang, M., Holman, C. D. J., Price, S. D., Sanfilippo, F. M., Preen, D. B., & Bulsara, M. K. (2009) · BMJ · doi:10.1136/bmj.a2752 · Cited by 208
Chuang, S. K., Wei, L. J., Douglass, C. W., & Dodson, T. B. (2002) · Journal of Dental Research · doi:10.1177/154405910208100814 · Cited by 208
A systematic review of hospitalization resulting from medicine‐related problems in adult patients
Al Hamid, A., Ghaleb, M., Aljadhey, H., & Aslanpour, Z. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12293 · Cited by 207
Tamblyn, R., Eguale, T., Huang, A., Winslade, N., & Doran, P. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1705 · Cited by 196
Self-citationConcealed Renal Insufficiency and Adverse Drug Reactions in Elderly Hospitalized Patients
Corsonello, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.790 · Cited by 193
Assessing the Economic Impact of Adverse Drug Effects
Rodríguez-Monguió, R., Otero, M. J., & Rovira, J. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321090-00002 · Cited by 177
Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary Care
Eguale, T., Buckeridge, D. L., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. M. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.340 · Cited by 159
Self-citationHutchinson, T. A., Flegel, K. M., Kramer, M. S., Leduc, D., & Kong, H. H. P. (1986) · Journal of Chronic Diseases · doi:10.1016/0021-9681(86)90198-0 · Cited by 156
A model for the future conduct of pharmacovigilance
WALLER, P. C., & Evans, S. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.773 · Cited by 136
Adverse Drug Events in U.S. Adult Ambulatory Medical Care
Sarkar, U., López, A., Maselli, J. H., & Gonzales, R. (2011) · Health Services Research · doi:10.1111/j.1475-6773.2011.01269.x · Cited by 133
Risk Factors Associated with Adverse Drug Reactions Following Hospital Admission
Zopf, Y., Rabe, C., Neubert, A. C., et al. (2008) · Drug Safety · doi:10.2165/00002018-200831090-00007 · Cited by 97
Chen, D. T., Wynia, M. K., Moloney, R., & Alexander, G. C. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1825 · Cited by 97
Prioritizing Future Research on Off‐Label Prescribing: Results of a Quantitative Evaluation
Walton, S. M., Schumock, G. T., Lee, K., Alexander, G. C., Meltzer, D. O., & Stafford, R. S. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.12.1443 · Cited by 95
Finding the Meaning in Meaningful Use
Classen, D. C., & Bates, D. W. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1103659 · Cited by 91
France's New Framework for Regulating Off-Label Drug Use
Emmerich, J., Dumarcet, N., & Lorence, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208347 · Cited by 73
Galanter, W., Falck, S., Burns, M., Laragh, M., & Lambert, B. L. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001555 · Cited by 65
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. (1998) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(98)80042-5 · Cited by 65
Eguale, T., Winslade, N. E., Hanley, J. A., Buckeridge, D. L., & Tamblyn, R. M. (2010) · Drug Safety · doi:10.2165/11534580-000000000-00000 · Cited by 47
Self-citationMonitoring the Safety of Medicines Used Off-Label
Pan, G. J. D. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.24 · Cited by 38
Seizure Activity and Off-Label Use of Tiagabine
Flowers, C. M., Racoosin, J. A., & Kortepeter, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055301 · Cited by 37
Avorn, J., & Kesselheim, A. S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00010 · Cited by 34
Detection of Adverse Drug Events and Other Treatment Outcomes Using an Electronic Prescribing System
Eguale, T., Tamblyn, R. M., Winslade, N. E., & Buckeridge, D. L. (2008) · Drug Safety · doi:10.2165/00002018-200831110-00005 · Cited by 32
Self-citationComputerized prescriber order entry: Models and hurdles
Schiff, G. D. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.15.1456 · Cited by 14
Cited by
Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Self-citationOff-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
Bronskill, S. E., Campitelli, M. A., Iaboni, A., Herrmann, N., Guan, J., Maclagan, L. C., Watt, J., Rochon, P. A., Morris, A. M., Jeffs, L., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15519 · Cited by 54
Off-Label Use vs Off-Label Marketing of Drugs
Van Norman, G. A. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.12.011 · Cited by 49
Gjerden, P., Bramness, J. G., Tvete, I. F., & Slørdal, L. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2281-8 · Cited by 48
Metadata
- Authors
- Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-01-01
- Volume
- 176
- Issue
- 1
- Pages
- 55
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2157789635
- Cited by
- 262
- References
- 42
- FWCI
- 41.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.